Merck Tbk PT

Merck Tbk PT EBITDA per Share

The EBITDA per Share of Merck Tbk PT (MERK.JK) as of Nov 3, 2026 is 715.25 IDR. In the previous year, EBITDA per Share was 449.00 IDR — a change of 59.30% (higher).

EBITDA per Share

715.25IDR

YoY

59.30%

Last updated:

EBITDA per Share of Merck Tbk PT is 2025 715.25 IDR. EBITDA per Share of Merck Tbk PT was 2024 449.00 IDR. It decreases by 59.30% higher compared to the previous year.

The Merck Tbk PT EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
111.26 IDR
Jan 1, 2019
286.88 IDR
Jan 1, 2020
266.54 IDR
Jan 1, 2021
450.23 IDR
Jan 1, 2022
552.95 IDR
Jan 1, 2023
465.35 IDR
Jan 1, 2024
449.00 IDR
Jan 1, 2025
715.25 IDR
The Merck Tbk PT EBITDA per Share history
YEAREBITDA per ShareYoY
715.25IDR+59.30%
449.00IDR-3.51%
465.35IDR-15.84%
552.95IDR+22.81%
450.23IDR+68.92%
266.54IDR-7.09%
286.88IDR+157.84%
111.26IDR-76.43%
472.02IDR-2.29%
483.09IDR+13.47%
425.73IDR-6.24%
454.08IDR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Merck Tbk PT Stock analysis

What does Merck Tbk PT do? Merck Tbk PT generates revenue through its Biopharma segment, which focuses on ethical pharmaceutical products for serious diseases. The company also earns from Consumer Health, offering over-the-counter products that support personal wellness and family planning needs. Its 'Others' segment includes additional business activities. The firm serves healthcare providers, pharmacies, and individual consumers seeking personalized treatments and accessible health solutions. Biopharma targets medical professionals and hospitals with specialized treatments for critical conditions. Consumer Health products are sold directly to consumers through retail channels for daily health management. The company's business model relies on delivering tailored healthcare solutions across its three operational segments to meet diverse market demands. Merck Tbk PT's revenue streams are structured around pharmaceutical innovations and consumer health products. Ethical products in Biopharma address unmet medical needs, while over-the-counter offerings in Consumer Health cater to everyday health requirements. The firm's focus on personalized care ensures consistent demand from both professional and individual customers. Merck Tbk PT is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merck Tbk PT stock

EBITDA per Share of Merck Tbk PT is 715.25 IDR in 2025.

EBITDA per Share of Merck Tbk PT changed from 449.00 IDR to 715.25 IDR, representing a 59.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Merck Tbk PT since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Merck Tbk PT

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Merck Tbk PT